Author name: admin22

FDA Approves First Drug Shown to Help Patients with Infantile Onset Niemann-Pick Disease Type C Live Longer

The FDA has approved Lembaz (adrabetadex), the first treatment shown to reduce the risk of death in patients with infantile onset Niemann-Pick disease type C (NPC), a rare inherited disease that causes progressive neurological decline. Lembaz received Breakthrough Therapy designation. The FDA granted approval of Lembaz to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC.

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide

The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA’s regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA’s global leadership and may accelerate patient access …

FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide Read More »

FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer

On November 17, 2026, the Food and Drug Administration granted accelerated approval to neladalkib (Nelkarmi, Nuvalent, Inc.), a kinase inhibitor, for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine …

FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer Read More »

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

On November 16, 2026, the Food and Drug Administration approved giredestrant (Wilserdly, Genentech, Inc.), an oral estrogen receptor antagonist, in combination with everolimus for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorized test, …

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer Read More »

iPLEDGE REMS Modifications Have Been Implemented and Are Live for Isotretinoin, a Medication for Severe Acne

The iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) modifications were implemented yesterday, November 15, 2026. The iPLEDGE REMS is a safety program to mitigate the risk of isotretinoin, which can result in harm to fetal development. Isotretinoin is approved to treat severe nodular acne that has not responded to other treatments in non-pregnant patients 12 years and older.

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy

The U.S. Food and Drug Administration has approved Gazyva (obinutuzumab) injection to treat adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria (protein in the urine). This is the first drug approved specifically for the treatment of adults with primary membranous nephropathy. Gazyva was previously approved for treating certain …

FDA Approves First Drug to Treat Adults with Primary Membranous Nephropathy Read More »